Rates of contributory de novo mutation in high and low-risk autism families. by Yoon, Seungtai et al.
ARTICLE
Rates of contributory de novo mutation in high and
low-risk autism families
Seungtai Yoon1,7, Adriana Munoz1,7, Boris Yamrom1, Yoon-ha Lee1, Peter Andrews1, Steven Marks1,
Zihua Wang1, Catherine Reeves 2, Lara Winterkorn2, Abba M. Krieger3, Andreas Buja3, Kith Pradhan4,
Michael Ronemus1, Kristin K. Baldwin5,6, Dan Levy1, Michael Wigler1,2 & Ivan Iossifov 1,2✉
Autism arises in high and low-risk families. De novo mutation contributes to autism incidence
in low-risk families as there is a higher incidence in the affected of the simplex families than in
their unaffected siblings. But the extent of contribution in low-risk families cannot be
determined solely from simplex families as they are a mixture of low and high-risk. The rate
of de novo mutation in nearly pure populations of high-risk families, the multiplex families,
has not previously been rigorously determined. Moreover, rates of de novo mutation have
been underestimated from studies based on low resolution microarrays and whole exome
sequencing. Here we report on findings from whole genome sequence (WGS) of both sim-
plex families from the Simons Simplex Collection (SSC) and multiplex families from the
Autism Genetic Resource Exchange (AGRE). After removing the multiplex samples with
excessive cell-line genetic drift, we find that the contribution of de novo mutation in multiplex
is significantly smaller than the contribution in simplex. We use WGS to provide high
resolution CNV profiles and to analyze more than coding regions, and revise upward the rate
in simplex autism due to an excess of de novo events targeting introns. Based on this study,
we now estimate that de novo events contribute to 52–67% of cases of autism arising from
low risk families, and 30–39% of cases of all autism.
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Autism is a neurodevelopmental disorder with a stronggenetic component. This was first inferred by the greaterconcordance of monozygotic twins than dizygotic twins
and an increase in risk to the siblings of an affected child. The
importance of genetics was later directly demonstrated by finding
a higher incidence of de novo gene disruption in affected than
unaffected siblings within families with only a single affected
offspring (simplex families)1–12. This observation, plus the higher
incidence of autism in males than females (3:1), the observed rate
of ~25% concordance for boy siblings, and the nearly 50% inci-
dence of autism in the third born male child of multiplex
families13 led to what we call the “unified genetic theory for
sporadic and inherited autism” in 2007. In this theory we con-
jectured two risk classes of families. We proposed that highly
penetrant de novo mutations contribute to most low-risk families
and that transmission from a carrier parent contributed to autism
in most high-risk families. We used data on sibling risk and brood
size to estimate that roughly half of autism arises from low-risk
families and half from high-risk families14,15.
We still lack a clear demonstration that low and high-risk
families are truly distinct in their genetic causation. The role of de
novo mutations has been firmly demonstrated in collections of
simplex families that would be expected to contain mainly low-
risk families. On the other hand, the incidence of de novo
mutation in multiplex families, which would be expected to be
almost exclusively high-risk, has been equivocal5,7, and it is
known that common variation plays a substantial role in autism
heritability16,17. Unlike the simplex collections, largely drawn
from blood, many of the multiplex collections are drawn from
EBV-immortalized lymphoid cells maintained in culture. These,
due to oligo-clonality and/or cell-line genetic drift, have an excess
of somatic artifacts, rendering measurement of de novo rates
problematic. We have sought to compare the rates in simplex and
multiplex collections by controlling for drift in the latter. Our
results of low rates in multiplex confirm a recent study of the
same population18.
Basing the contribution of de novo variants in simplex collections
solely on large copy number events (CNV) and the likely-gene
damaging (LGD) coding mutations will lead to underestimates. A
great deal of uncertainty still exists for the role of missense muta-
tions, the full contribution from CNVs and other structural rear-
rangements, and only preliminary attempts have been made in the
non-coding space19–25. Thus, quantifying the role of de novo
mutation in simplex families is still an open problem.
In this paper we used the newly generated whole genome
sequencing (WGS) data from large multiplex (AGRE) and large
simplex (SSC) family collections to compare the contributions of de
novo variants in low and high-risk families and to evaluate the role of
de novo intronic variants in SSC. We consider large scale copy
number events, small indels, and substitutions. First, however, we
identify the AGRE multiplex samples with extensive somatic genomic
drift by the presence of two hallmarks: (1) excess single nucleotide
variations throughout the entire genome; and (2) a preponderance of
variants with unexpected allele ratios. Removing these samples, we
then measure rates of de novo events in the remainder. From this
new data, we make better estimates of contribution of de novo
mutation in collections of simplex and multiplex families. Our ana-
lysis points to a substantial contribution of de novo variants in
introns. From our results we update estimates of the contribution of
de novo events in high and low-risk families and in autism overall.
Results
Comparing de novo rates in multiplex and simplex families
Filtering multiplex samples with excessive cell-line genetic drift.
Some of the AGRE DNAs used for WGS were extracted from
cultured lymphoblastoid cell lines (LCL), and some from whole
blood (WB). In contrast all of the SSC DNA was extracted from
whole blood (WB). Samples from LCL pose a risk: without care,
the large number of events acquired during cell culture or
immortalization will be mistaken for germline mutation. These
artifacts are made evident in the AGRE by examining the fre-
quency and allele ratios of the substitutions observed in the
children but not in either parent (Fig. 1). For each child-sample
we display in a scatter plot its number of “acquired” substitutions
adjusted for coverage (X-axis) and the mean ratio of hetero-
zygosity for those substitutions (Y-axis). The distributions of
these two properties are shown in the margins for the LCL from
AGRE (blue), the WB from AGRE (green), and the WB from the
SSC (yellow). Clearly the WB data from AGRE and SSC show
Fig. 1 Cell-line genetic drift filter. Each dot represents a data point from
one individual child. Individuals from AGRE for which DNA was extracted
from LCLs (AGRE LCL) are colored blue, individuals from SSC, for all of
which DNA was extracted from whole blood (SSC WB) are colored yellow,
and individuals from AGRE extracted from whole-blood DNA (AGRE WB),
are colored green. We adjusted the number of observed de novo
substitutions based on the power for detection of de novo SNVs estimated
separately for every child (see Materials and Methods for description of
procedure for power estimation and Supplementary Figure 2). We set the
adjusted number of de novo substitutions to the observed number of de
novo substitutions divided by the estimated power and show it on the
X-axis in linear scale for numbers smaller than 150 (the vertical dashed
line) and in log-scale for larger numbers. For every child, we assigned the
mean alternative allele ratio based on the alternative allele ratios (defined
as the proportion of the sequencing reads converting the position that
support the alternative allele) for each of the de novo substitutions
identified in the child. The mean alternative allele ratios are shown on the
Y-axis. Density plots in the top and right sides show marginal distributions
of corresponding cohorts by color. We modeled the WB data from SSC and
AGRE as a two-dimensional Gaussian distribution over the power adjusted
number of de novo substitutions and the mean alternative allele ratio and
we established an ellipse (shown in black) that would include 99.9% of the
Gaussian distribution density. Children within the ellipse are considered
free of cell-line genomic drift. We show in the inset the total number of
children in each of the three groups together with the number of children
that were determined to be free of cell-line genetic drift.
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similar distributions. On the other hand, the LCL data is multi-
phasic, with one phase in agreement with WB.
To identify the usable samples, we modeled the WB data as a
two-dimensional Gaussian distribution on the variables of allele
count and ratio (see Fig. 1 and Supplementary Data 1). We then
established an ellipse that would exclude 0.1% of the Gaussian
distribution. This ellipse empirically excludes about 0.3% (13 out
of 3756) of the WB samples. We consider the samples in the
ellipse to be free of cell-line genetic drift. We then apply the same
filter to the LCL of the AGRE, and thereby exclude an excess of
50% of those (1062 out of 1929). We note that our method
of filtering agrees very well with the machine learning method of
Ruzzo, et al.18, even though the latter is conditioned on the
variant and not the sample. Consistent with our analysis based on
substitutions, the same samples with detected cell-line genetic
drift have an excess of acquired CNVs (Supplementary Fig. 1 top
two panels), and many of these CNVs do not have integer copy
number (Supplementary Fig. 1 bottom two panels).
Comparing AGRE and SSC for small scale de novo mutations in
genes. For the rest of the analysis, we selected three groups from
the trios passing the sample cell-line genetic drift filters: 1,874
unaffected children from SSC; 1,869 affected children from SSC;
and 1,107 affected children from AGRE. There were not enough
of the unaffected siblings from AGRE for meaningful analysis. In
selected children, we identified small scale de novo events, both
substitutions and small indels, using previously published
methods2,11 (see Materials and Methods, Supplementary Data 2
and Supplementary Data 3 for the list of all small scale de novo
variants identified). These small events were then divided into six
likely functional classes and counted: LGD (likely gene disrupting,
consisting of nonsense, frameshift, or splice site mutations);
synonymous (SYN); intronic substitutions (ISB) and small indels
(IID); and intergenic substitutions (IGSB) and indels (IGID). We
consider the SYN, IGSB, and IGID as free of any bias due to
affected status because they will be largely without functional
consequence. We do not consider in this paper missense sub-
stitutions, because their functional significance is too difficult to
assess. Moreover, we exclude from consideration events on the
X-chromosome.
We are interested in determining the extent to which LGD
incidence is increased due to the affected status of the child within
its family type. These must be adjusted for coverage, parental age,
and possible cell-line genetic drift. The three groups of children
were not identical in (1) depth of WGS coverage and (2)
distribution of the ages of their parents (see Supplementary
Fig. 2). Moreover, there is the possibility that (3) we have not
completely filtered all cell line drift. These three factors clearly
influence the rate of the observed de novo variants. To control for
these variable rate factors, we used SYN mutations. SYN and
LGDs are both located in protein coding regions and are likely to
be affected similarly by parental ages, sequence coverage, and
drift. We thus use de novo SYN incidence as a normalization
factor for the comparison of LGD incidence in different
populations, as we and others have done in the past26.
We outline here the method we use to compare the incidence
of the subject class of LGD de novo variants in a group of SSC
unaffected and a group of either AGRE or SSC affected using a
normalization by of de novo SYN variants. We assume that the
subject class (LGD) may be biased based of the affected status
while the normalization class (SYN) is not, but that both classes
are equally influenced by the covariates parental ages, sequence
coverage and cell-line genetic drift. We are interested in two
measures quantifying the role of the subject class in the affected
group, the ascertainment differential (AD) and percent con-
tributory (PC). The AD measures the excess of events above the
estimate of expected number of observations of that subject class
given the null hypothesis that these mutations had not
contributed to the diagnosis. We compute the expected number
of observations in the affected by this equation:
ES:a ¼ S:u  ðN:a=N:uÞ ð1Þ
where ES.a is the expected number of observations of the subject
class in the affected group, S.u is the actual observed number of
that class for the unaffected group, N.a is the observed number of
the normalization class in the affected, and N.u is the observed
number of that class in unaffected. The ascertainment differential
(AD) for the affected group is defined as the difference between
the number of observed events and the expected number, divided
by the number of children in the group, and expressed as a
percentage of children:
AD ¼ 100  ðS:a ES:aÞ=C:a; ð2Þ
where the S.a is the observed number of the subject class in the
affected group and C.a is the number of affected children in that
group. We interpret AD as the percent of affected children that
were diagnosed with autism due to a contribution from the given
subject class, given the assumption that the expected number of
contributory events per child is smaller than 1. We define the
second measure, the percent contributory (PC), with this formula:
PC ¼ 100  ðS:a ES:aÞ=S:a: ð3Þ
We interpret PC as the percent of the subject class events in the
affected group that have contributed to the disorder.
We compute a p-value of the AD under the null hypothesis: the
subject class does not contribute to the disorder. This p-value is
determined empirically as the likelihood of the observed AD
arising from the data when we permute the labels “affected” and
“unaffected”. Specifically, we measure the probability to achieve
AD larger or equal to the observed AD under normal distribution
fitted to ADs derived from 1,000 trials permuting the affected and
unaffected, keeping the numbers of each group fixed. We also
compute confidence intervals (CI) for the AD and the PC using
1,000 bootstrap iterations, sampling with repetition the same
number of children from the set of the affected and unaffected.
With these methods we examined de novo LGD, a class of
variant that is known to contribute to autism in simplex families.
While most of the previous studies of ascertainment bias in this
class was based on whole exome sequencing of the SSC, in this
instance we have WGS from both the SSC and AGRE.
The AD and PC for the de novo LGDs in affected children
from SSC are 6.48% (CI: 3.85 to 8.80) and 42.8% (CI: 27.8 to 54.3)
respectively with p-value 8 × 10−7 (Table 1). These results are
consistent with the well-established causal role of de novo LGDs
in simplex autism2,8,10,12,27, and are comparable to previous
results from WES. The AD and PC for the affected children for
the multiplex families in AGRE are 1.42% (CI: −1.25 to 4.15) and
13.6% (CI: −13.4 to 35.1) with p-value of 0.14.
These results suggest that de novo LGDs contribute to autism
in the high-risk multiplex families, but the contribution is most
likely less than a quarter of the contribution of such variants in
simplex families. The AD measures in the two affected groups are
statistically different, with p-value of 0.001 computed by directly
comparing the two groups of affected.
Comparing AGRE and SSC for large scale de novo mutations. We
developed a pipeline for detection of de novo CNV events which
was based on two different methods and a set of stringent filters
to avoid false-positive calls (e.g. cryptic transmission). The
pipeline is described in the Materials and Methods and Supple-
mentary Note 1 and all detected events are listed in Supple-
mentary Data 4. As we did for the small-scale events, we
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compared the affected children in SSC and AGRE to the unaf-
fected in SSC and restricted the analysis only to the children that
passed the sample cell-line genetic drift filters. As discussed above
the three groups of children differ in the ages of their parents and
in the sequence coverage. We ignored the difference of parental
ages because there is no well-documented relationship between
parental ages and rates of de novo CNV. Moreover, we see no
evidence for such relationship in our data. We examined the
effects of coverage in the three groups on the power of our
pipeline to detect de novo CNVs by simulating artificial CNVs of
various sizes (see legends and Materials and Methods). The
results (Supplementary Fig. 4) show that the power is the same
for the affected and unaffected children from SSC across all CNV
sizes (from 1 kb to 100 kb). But the power to detect small (<4 kb)
CNVs in the data from the AGRE affected is diminished. In
comparing the SSC to AGRE families, therefore, we ignored the
CNVs smaller than 4 kb. We simplified the definitions of AD and
PC to avoid the normalization for coverage and parental ages by
using the number of children instead of the number of de novo
variants of a normalization class.
Table 2 summarizes the relevant incidence data for de novo
CNV from the three groups of children separately. We further
partition CNVs into: ‘intergenic’, meaning not overlapping the
transcript of any gene listed in RefGene; ‘coding’, meaning any
event overlapping the coding regions of a RefGene; and ‘genic
noncoding’, meaning any event that overlaps a transcript of a
RefGene but without overlapping coding regions (Fig. 2).
In the SSC there is strong statistical evidence for an excess for
events that disrupt coding regions (p-value= 4 × 10−7, AD=
3.32% (CI: 2.04 to 4.63), PC= 58.6% (40.9 to 71.0)). PC increases
as copy number events hit more genes (see Supplementary Fig. 5),
rising from 40% for events hitting one or more genes to 85% for
events hitting five genes of more. The increasing impact of
multigenic events has been previously noted3. There is no signal
in the ‘intergenic’ or the ‘genic noncoding’ class (p-values= 0.15
and 0.41 respectively) for CNVs with size of at least 4 kb. In
AGRE, there is no evidence for all CNV events (p-value: 0.29).
There was a marginally significant excess of coding de novo
CNVs (p-value: 0.12, AD= 0.72%, PC= 23.6%). This AD for
coding CNVs in AGRE is about one quarter of the AD for SSC,
with the difference being highly significant (p-value: 0.0007) using
permutation testing.
Aggregated signals from de novo CNVs and LGDs. We analyzed
the aggregated burden of de novo LGD and de novo coding
CNVs in the affected of the SSC and AGRE by a permutation
method (Table 3). The AD for the aggregated events is 9.80% (CI:
6.91 to 12.46, p-value= 5 × 10−11) for the SSC affected, and
2.15% (CI: −0.64 to 5.03, p-value= 0.062) for the AGRE affected.
The aggregated ADs are roughly equal to the sum of the ADs for
the individual event types. The aggregated AD for the affected
children in the multiplex AGRE families is only marginally sig-
nificant and its magnitude is a quarter of the AD for the simplex
families in SSC. The direct comparison of the rates of the
aggregated events shows that the two groups of affected children
are significantly different (p-value: 10−5).
Contribution of de novo intron mutations to children from
simplex families
De novo CNVs. The ~30X WGS data enables us to observe smaller
de novo CNVs than was possible with microarrays or WES. By
simulation we show that, for the SSC, we have power of nearly 90%
to detect events of size 1 kb from the WGS data, with equal power
for both affected and unaffected children (Supplementary Fig. 4). In
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by class: coding and genic noncoding. The latter is divided into
‘intercoding intronic’, meaning exclusively between coding exons;
and ‘peripheral’ meaning genic events overlapping UTRs or the
introns splitting UTRs. There is clear signal from single gene events
(p-value= 0.027), a finding that is predicted, but was not clear from
our previous studies based on microarrays due to insufficient
resolution. The AD 1.18% divides between coding (p-value= 0.12)
and intercoding intronic (p-value= 0.0068). Although not statisti-
cally different, the PC for the intercoding intronic class (57.8%) is
higher than for the coding class (24.6%). The peripheral regions
show no signal, but the counts are low (5 in affected and 4 in
unaffected). Other researchers report de novo targets in ‘regulatory’
domains in the periphery of genes21, and we discuss this later.
Small de novo events. We identified extra support for the role of
intercoding intronic regions by examining the de novo insertion-
deletion events (indels) in intercoding intronic regions (IID) in SSC.
These events were detected by the same sequence analysis pipeline
we used to identify de novo LGD variants. The rate of de novo
indels is influenced by age of parents (Supplementary Figure 6) and
coverage, so we used de novo intergenic indels (IGID) as the nor-
malization class for the comparison of incidences of de novo IIDs in
the affected and unaffected children in SSC. We excluded the var-
iants that directly affected the canonical splice-site regions. Our
expectation of overall statistical signal was low, due to larger
background and lower likelihood of impact for small events. Indeed,
we see large numbers of intronic de novo indels in the SSC, with no
signal of an ascertainment bias overall (Table 5, rows 1) in affected
versus their unaffected siblings (p-values of 0.25).
To enhance our ability to detect signal, we therefore focused on
the introns of genes that we expected to have a more favorable
signal to noise ratio, namely those genes already identified as
probable targets by prior studies. From Denovo-db28, we obtained
two lists of genes targeted by de novo LGDs, either in children
with autism (748 genes) or more generally in multiple neuro
developmental disorders (1,521 genes) (see Table 5 and
Supplementary Data 5). In both of these sets of genes, we see
statistical signal for IID, with AD of 2.82% (CI: from −0.16 to
−5.55) and p-value of 0.026 for the autism targets and AD of
5.01% (CI: from 1.17–8.69) and p-value of 0.008 for all
neurodevelopmental disorder targets. In contrast, the control
sets of genes show no significant difference of IID rates between
affected and unaffected siblings. As with de novo CNVs, we see
no signal from indels in the peripheral regions (See Fig. 2 and
Supplementary Table 1).
We similarly examined the role of de novo intercoding intronic
substitutions (ISB) using IGSB for normalization. We saw no
signal for de novo ISB in either the overall intronic space or the
introns of target genes. Given the enormous background of
neutral substitutions, loss of signal from functional mutation is
not surprising. We quantified our expectations by power
calculations. The likelihood of observing statistically significant
signal (p-value <= 0.05) from intronic substitutions in the
intronic space is shown in Supplementary Figure 7, for all gene
targets and for all candidate target genes. The power to detect a
5% contribution in a collection the size of the SSC is nearly 0
overall and around 0.2 for the autism target genes. Yet, it is
unlikely that de novo intronic small indels contribute to the
disorder while de novo intronic substitutions do not: the former
cause greater damage per event, but the latter are about ten times
more common.
We searched for mechanism of action by exploring the
properties of the de novo INDs and ISBs that could reasonably
be hypothesized to be contributory. These properties were:
lengths of the indel; lengths of the affected introns; the proximity
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conservation at the mutated site; and the likelihood of creation of
a new splice site. We also searched by the length of the largest
open reading frame at the indel site, which might indicate the
mutation affected an unannotated exon. We associated all de
novo intronic events (both indels and substitutions) with each of
the above properties, and then asked if the distributions of these
properties differed significantly among subsets of the de novo
events. These subsets were determined by mutation type (indel or
substitution), the affected status of the child, and the target gene
class (e.g., ‘all genes’ and ‘affected LGD targets’). None of our
efforts produced a statistically significant signal. However, some
of our observations were in a positive direction. Our entire
analysis is reported in the Supplementary Note 2, Supplementary
Table 2, and Supplementary Figure 8–34.
Estimating the burden of de novo events to autism. Based on
the results we have presented, we make a fresh estimate of the
contribution of de novo events to autism incidence. We start with
simplex families (Table 6). In this paper we estimate de novo
CNVs contribute in ~4% of families. This is slightly lower than
previous estimates, but our methods are very conservative. The
estimates from LGDs (9%) and from missense (12%) derive from
previous studies. These sum to 25%. In the present work we
estimate the contribution from de novo CNVs and de novo small
indels in the intronic space to be ~1% and ~5% respectively.
Based on the study by An, et al.21 we further estimate con-
tributory de novo promoter events at about 7%. The projected
contributions from these two noncoding sources sum to 13%,
about half the projected 25% contribution from coding events.
Together they total 38%. We have not tallied certain de novo
variant types, such as de novo intronic substitutions and struc-
tural variants at highly repetitive regions of the genome. More-
over, parental29,30 and somatic31–33 mosaicisms are often
excluded in searches for de novo events. Thus, we may have
underestimated contribution from de novo events. Given all the
uncertainty, we estimate that de novo events of all types con-
tribute to 35–45% of autism from simplex families.
Next, we estimate the contribution of de novo variants
separately for the high-risk and low-risk families. We can
approximate the de novo contribution in the high-risk families,
H, as equal to our estimate of the contribution in multiplex
families. Based on our findings that the contribution in multiplex
families is about a quarter of the contribution in simplex families
(Table 3), and given our estimate of the contribution in simplex
families, S= 35–45%, we estimate that H= 9–11%. The con-
tribution to low-risk families, L, can then be computed using the
estimates for the proportion of simplex families of low (pLs= 0.6)
and high (pHs= 0.4) risk we made in Ronemus, et al.15. From the
following equation:
S ¼ pLs  Lþ pHs  H: ð4Þ
we arrive at the estimate of the contribution to the low-risk
families L= 52–67%.
Finally, using the de novo contributions in low (52–67%) and
high-risk (9–11%) families and the estimate that half of autism
cases originate from low-risk families and half from high-risk
families14,15, we compute that the de novo contribution to overall
autism is 0.5*(52–67%)+ 0.5*(9–11%), or 30–39%. We arrive at
a similar estimate using a second, more direct way for calculating
the de novo contribution to autism overall that depends on the
empirical measure of the proportion of autism cases in simplex
and multiplex families. The growing SPARK collection provides
such an estimate. In release 4 of the registered families there are
13,775 affected children from 6,505 multiplex families and 65,184
children from simplex families, giving us proportions of 0.17
(13,775 / (13,775+ 65,184)) cases in multiplex families and 0.83
cases in simplex cases. Combining these proportions with
estimated de novo contributions in simplex and multiplex cases
we arrive at 0.83 * 35–45% + 0.17 * 9–11%= 30.5–39.1%.
Discussion
In our prior work14,15 we presented a simple model (the unified
hypothesis) connecting de novo mutation and transmission in
which we postulated high and low-risk autism families. The
model explained the observation we made from analysis of
multiplex families that the chance for autism is nearly 50% in a
male born into a family with two or more prior children with
autism14. This latter observation was confirmed by others using
independent collections13, and is now confirmed in the latest
release of the SPARK collection comprising more than 70,000
families with autism (work in progress). The model also explained
our observation, based on a small study, that causal de novo
mutation was relatively absent in multiplex families1. Unlike our
observation of sibling risk in multiplex families, this result was
contradicted in some other studies5,7. We felt these contradictory
Fig. 2 Event types. We assign a label ‘intergenic’ (purple) to any event that
falls between transcripts; a label ‘coding’ (brown) is assigned to events that
affect coding exons; a label ‘intercoding intronic’ (green) is assigned to
events that affect an intron splitting two coding exons; a label ‘peripheral’
(blue) is assigned to events that affect coding transcripts but are neither
coding nor ‘intercoding intronic’; a label ‘noncoding’ (yellow) is assigned to
events that affect noncoding transcripts. The peripheral events affect the
untranslated regions of the coding transcripts (UTRs) or the introns that
split UTRs. We use RefSeq transcript models downloaded from the UCSC
genome browser to find the genomic coordinates the exons38.
Table 3 Combined de novo LGDs and coding CNVs in simplex and multiplex autism.
Group Events number Expected events number delta p-value AD
SSC affected 389 205.7 183.3 5 × 10−11 9.80% (6.91–12.46)
AGRE affected 150 126.2 23.8 0.062 2.15% (−0.64–5.03)
The table shows our joined analysis of the de novo LGDs and the coding de novo CNVs that allowed us to avoid the assumptions of independence between the two classes. The “events number” column
shows to total number of de novo LGDs and de novo coding CNVs larger than 4KB in the two groups of affected children. The “expected events number” was computed by using the appropriate
normalization factor for the two classes: number of de novo synonymous variants for de novo LGDs and the number of children for the coding de novo CNVs. Table 1’s legend describes the “delta”,
“p-value”, and “AD” columns.
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studies were flawed, having failed to take into account genetic
drift of cells in culture. We resolve this question in the
current study.
Unlike the samples of the SSC, in which DNA derives directly
from blood, the DNA of many autism sample collections,
including much of the AGRE, derive from cultured EBV infected
lymphocytes. We demonstrated here that DNAs from some of the
cultured cells of AGRE, though not all, display far greater cell-line
genetic drift than seen in blood derived DNAs (see Fig. 1). Our
results confirm the recent parallel study by Ruzzo et al.18 on the
same data set. They too seek to remove artifacts of drift, although
we use different methods. They filtered individual events, using
machine learning techniques, while we filtered samples. The drift
in samples creates the appearance of large numbers of de novo
events in those samples, both substitutions and copy number, and
we eliminated all events in such samples. When such samples are
removed, the remaining samples from AGRE match the de novo
variant characteristics for frequency and allele bias that we see in
the SCC (Fig. 1).
With noisy samples removed, we observe, as did Ruzzo, et al.18,
that the incidence of de novo LGDs in autism from multiplex
families is significantly lower than the incidence in autism from
simplex families (p-value: 0.001). In addition, we similarly
observe a significant lower incidence for de novo CNVs that
target genes (p-value: 0.0007). By combining these mutational
types into one class, we then observed less contribution from de
novo events in AGRE than in SSC affecteds, with a p-value of
10−5. These results therefore confirm our initial observations,
based on the AGRE collection when it was still new, that causal de
novo events are more prevalent in the simplex than in multiplex
autism.
Yet we do see a higher incidence of de novo LGD and CNVs
targeting genes in multiplex affected compared to the simplex
unaffected. Neither alone has statistical difference. However, if we
aggregate de novo CNVs and LGDs we find an elevated incidence
with a p-value of 0.062. Here we differ from Ruzzo, et al.18 who
examined only de novo LGDs in the same population and found
no difference in incidence. Using the simplex unaffected as
baseline, the ascertainment differential (AD) of de novo LGDs
and CNVs targeting genes in AGRE are each about one quarter
the AD for simplex affected.
WGS data enables us to directly examine the role of de novo
variants in the parts of the genome that are non-coding. Although
others have seen evidence of target in the promotor regions of
genes using specialized search tools, in the absence of such tools
we see no signal in the intergenic regions. However, our analysis
does find evidence of a role for de novo CNVs in introns (p-value
0.0068, Table 4) and de novo small indels in introns of known
neuro-developmental risk genes or the smaller subset of autism
candidate genes (p-values 0.008, and 0.026, respectively, Table 5).
We see no evidence for a role for de novo substitutions in this
area, but this is expected from power considerations: there are
vastly more substitutions than small indels or CNVs, and each of
the substitutions would be of less impact than indels or CNVs
(Supplementary Figure 7).
The ascertainment differential from CNVs is 0.80% and from
small indels is 5.01%, yielding a combined AD of about 6% in
simplex autism. Although, due to a limited power, we cannot
observe a contribution from nucleotide substitutions in introns in
the SSC population, we speculate that the contribution from
substitutions within introns is of similar magnitude to that of the
intronic small indels, or about 5%. Larger datasets would be
needed to provide an empirically derived estimates from this
source.
The extent to which introns were targets for disrupting de novo
mutation, which we estimated at one half of the rate of disrup-
tions in coding regions, surprised us. Given the complexities of
splicing and gene regulation it is perhaps not a surprise that we
saw no evidence for a predominant molecular mechanism. To
understand these mutations better will require a case by case
study of the RNA expression in the candidate cells, a study which
is possible because almost the entire SSC cohort is also repre-
sented as immortalized cells.
We have made preliminary estimates of the contribution of de
novo events to children with autism from low-risk (52–67%) and
high-risk (9–11%) families, and to autism overall (30–39%). It is
important to emphasize “preliminary” because, with the possible
exception of de novo LGDs and CNVs in simplex collections, all
the components used to make these estimates are not robust.
Improved estimates would require many more families, more
WGS on quads, and improved demographic data. However,
30–39% is possibly an underestimate, as it does not fully take into
account mutations in highly repetitive regions, many other kinds
of structural rearrangements, somatic mutations and parental
mosaicism. Indeed, consideration of parental age and autism
incidence would be more consistent with a substantially higher
number (Taylor, et al.34 and studies in progress). Our estimates
do not conflict with estimates of the proportion of families in
which genetic transmission contributes. These latter estimates
range variously from 40 to 90%16,35–37. As multiple mechanisms
(de novo, transmission, epigenetic, and environmental) will
contribute in many families, the sum of the proportionate con-
tributions from each source over the entire population will
exceed 100%.
Materials and methods
Whole genome datasets. The whole genome sequencing data for both the Simons
Simplex Collection (SSC) and the Autism Genetic Resource Exchange (AGRE)
were generated at the New York Genome Center. One lane of 150 paired-end reads
on the Illumina 10X instrument was utilized per genome, achieving a depth of
coverage of ~30X. We selected both affected and unaffected children from 1,878 of
the SSC quad families (comprised of mother, father, an affected and an unaffected
child) and 2,208 children (2,131 affected and 77 unaffected) from 859 nuclear
families from AGRE for which we were able to identify both de novo small-scale
and CNV variants. 279 of the AGRE children had DNAs extracted from whole-
blood and the remainder had DNA extracted from LCLs. 1,869 affected and 1,874
unaffected children from the SSC and 1,107 affected and 36 unaffected children
from AGRE passed the cell-line genetic drift filters. Supplementary Data 1 lists all
children assessed in the manuscript. Since the study was limited to previously












The contributions to autism from simplex families of the various types of de novo coding and
non-coding events are estimated from the literature or from this work. Contributions from de
novo CNVs derive from this work. The contribution from small indels within introns is based on
this work. The other contributions are estimates from the literature cited.
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existing coded data, the CSHL IRB designated this study as “Not human subjects
research” and therefore exempt from review.
De novo substitutions and indels methods. We identified de novo substitutions
and de novo short indels using the multinomial genotyper we have described
previously11 and used extensively in our analysis of whole exome sequencing data
from the Simons Simplex Collection2,15,26. To accommodate the lower coverage in
the whole genome sequencing data, we set the filters for acceptable de novo can-
didate to denovoScr ≥70 and chi2Score > 0.001. The identified de novo variants in
the cell-line genetic drift-free trios are listed in Supplementary Data 2 and Sup-
plementary Data 3 for the SSC and AGRE, respectively.
De novo CNV pipeline. We assembled a pipeline for the identifying de novo CNVs
based on two different methods, “EWT de novo CNV finder” and “HMM de novo
CNV finder,” both developed in house. Both methods analyze whole genome
sequence data from a population of individuals jointly to deal with sample and
regional biases, but are otherwise conceptually different. We combine the candidate
de novo variants from the two methods and apply further stringent filters to guard
against cryptic transmission. Detailed description of the de novo CNV pipeline
components is presented in Supplementary Note 1, Supplementary Fig. 35, and
Supplementary Data 6. We applied de novo CNV pipeline separately over the SSC
and AGRE data and the final list of the de novo CNVs in the cell-line genetic drift-
free children is presented Supplementary Data 4.
We compared our list of detected de novo CNVs to published de novo CNVs in
the children we examined from SSC (Sanders, et al.6) and AGRE (Leppa, et al.7).
We detected all 17 of the de novo CNVs reported in Leppa et al. and these are
included in our analysis. We also detected all but 6 (likely due to differences in the
sample labels) of the 204 de novo CNVs reported in Sanders et al. We also excluded
75 additional of the Sanders et al. de novo CNVs due to mosaicism detected in the
parents, to polymorphisms in the parental population at levels above what our
stringed filters allowed, or to children that did not meet our cell-line genetic drift
filters. Supplementary Data 7 lists the Sanders et al. events not included in the
current analysis and the reasons they were excluded. Supplementary Data 4, that
lists the de novo CNV included in our analysis, indicates which of the de novo
CNVs have been previously reported and clearly demonstrates that the WGS data
enabled us to identify substantial number of new de novo CNVs smaller than
resolution of the previous methods.
Power to detect de novo CNVs. In our analysis, we compared rates for de novo
CNVs across different groups children from the two collections, AGRE and SSC.
Although the sequence data from the two collections had similar quality and
coverage, it was essential to know if the small differences that existed affected the
power to detect de novo CNVs. We used a simulation-based test for measuring the
power to detect de novo CNVs from whole-genome data for a collection of trios.
The procedure used the bin values (the csb values described in Supplementary
Note 1) generated from the “EWT de novo CNV finder” method and specifically
tested the power to detect de novo deletions in male children using the EWT de
novo CNV finder. We applied the test for deletions of 10 different sizes from 1 kb
to 10 kb in three groups of children: the affected and unaffected males from SSC,
and the affected males from AGRE. In each case, we simulated 10,000 autosomal
deletions and checked how many of the simulated deletions could be detected by
the EWT de novo CNV finder. Each simulated de novo deletion was generated
using the following steps. First, we chose a random male trio; a random region of
the given size on the X-chromosome that did not overlap with the
pseudoautosomal regions, telomeric or centromeric regions; and a random region
of the same size on one of the autosomes that did not overlap with telomeric and
centromeric regions. We then took the real bin value matrix for the selected
chromosome for all trios for the test groups of children (male and female), and
replaced the bin values for the male child of the selected trio with the bin values
from the selected X-chromosome region for the same child. The updated matrix
was fed to the EWT de novo CNV finder. Finally, for each simulated deletion we
checked if the selected autosomal region overlapped with any of the candidate de
novo deletions for the selected child generated by the finder. See Supplementary
Figure 4 for results.
Power to detect de novo substitutions given different coverages. We measured
the power to detect de novo substitutions separately for each trio from the SSC and
AGRE collection (Supplementary Fig. 2 and Supplementary Data 1). For every trio
we selected 10,000 random genomic positions and obtained the number of reads
covering each of these positions in the mother, father, and the child (coverage). We
then simulated a count data for a de novo mutation. Parents had counts for the
reference allele equal to the observed coverage and 0 reads supporting the alter-
native allele. We used a random value from a binomial distribution Binomial
(p= 0.47, N= coverage for the child) to obtain a count for the alternative allele for
the child. The count for the reference allele was that set to the difference of the
child’s coverage and the count for the alternative allele. The resulting 2 (reference
and alternative allele) by 3 (mother, father, child) count matrix was fed to the
multinomial genotyper. The proportion of the 10,000 positions successfully
classified as a de novo variant by the multinomial genotyper was used as an
estimate of the power to detect SNV in for the trio.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
We obtained existing whole-genome sequence datasets for the Simons Simplex
Collection (SSC) and the AGRE collections that have already been used in published
manuscripts18,21,25. The SSC whole-genome sequence data can be obtained from Simons
Foundation Research Initiative (SFARI; https://www.sfari.org). The AGRE whole-
genome sequence data can be obtained from the Hartwell Foundation’s Autism Research
and Technology Initiative (iHART; http://www.ihart.org). Access to these resources is
subject to approval by the respective institutions. We used these whole-genome
sequencing data to identify de novo substitutions, de novo small indels, and de novo
CNV using the methods described above and in Supplementary Note 1. We provide the
complete lists of children and identified de novo variants together with all attributes used
in our analysis in Supplementary Data 1–5.
Code availability
The source code we used in our analysis is included in the public GitHub repository
https://github.com/iossifovlab/denovoInHighAndLowRiskPaper. In addition, we provide
the input data for these scripts together with the results of executing the scripts over the
provided input. The input is a copy of the Supplementary Data associated with
this manuscript, and we include it in the source code repository for convenience. Thus,
interested readers can: (1) study the code and the complete set of results that we discuss
in the manuscript, (2) re-run the scripts on the provided input to reproduce precisely our
analysis, and (3) use the scripts over input related to their work to perform similar
analyses. The official release (v1.0) of the repository can be accessed through https://
doi.org/10.5281/zenodo.5137986.
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